DMAReading the latest developments, it looks like GSK will not...

DMA

Reading the latest developments, it looks like GSK will not go via the FDA approval path to get Intravenous Relenza registered in the US, through standard clinical trial procedures. The last reporting that seems like the most current position was "IV Relenza is on hold" according to Stout.

However, it looks like it will be used as an experimental drug in South East Asia via WHO management. Perhaps this is not so bad, at least clinical data will become available through this project. This seems however will be trials conducted by people that are non GSK staffers such as Hayden and others.

Lets wait to see how this develops. Quicker the better


Cheers